Illumina, Inc.
ILMN
Rang in aandelen
#610
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis... Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Aandeelprijs
$264.64
Marktkapitalisatie
$39.96B
Verandering (1 dag)
0.75%
Verandering (1 jaar)
165.96%
Land
US
Handel Illumina, Inc. (ILMN)
Categorie
Healthcare
Winst voor Illumina, Inc. (ILMN)
Winst in Jun 2026 TTM: $1.02B
Volgens de meest recente financiële verslagen van Illumina, Inc. bedraagt de huidige winst van het bedrijf $1.02B. In 2024 behaalde het bedrijf een winst van $-1.18B, een daling ten opzichte van de winst van 2023, die $-1.12B bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Illumina, Inc. van 2000 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.02B | -6.54% |
| 2025 | $1.09B | -192.11% |
| 2024 | $-1.18B | 5.55% |
| 2023 | $-1.12B | -226.36% |
| 2022 | $884.00M | 3.27% |
| 2021 | $856.00M | -23.43% |
| 2019 | $1.12B | 25.06% |
| 2018 | $894.00M | -14.29% |
| 2017 | $1.04B | 85.92% |
| 2016 | $561.00M | -3.77% |
| 2015 | $583.00M | 29.91% |
| 2014 | $448.76M | 181.68% |
| 2013 | $159.31M | -28.43% |
| 2012 | $222.61M | 67.32% |
| 2011 | $133.05M | -28.23% |
| 2010 | $185.38M | 62.44% |
| 2009 | $114.13M | 57.01% |
| 2008 | $72.69M | -125.17% |
| 2007 | $-288.79M | -777.58% |
| 2006 | $42.62M | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $7.61B | 649.66% |
US
|
|
| $4.76B | 369.16% |
US
|
|
| $-252.70M | -124.90% |
US
|
|
| - | - |
CN
|
|
| $1.66B | 63.35% |
US
|
